Frontlight ResearchEarly access
Active, not recruitingPhase 3
Treat-CMV
Key facts
- Who runs it
- UZ Leuven
- Where
- Belgium7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 112 people, planned
- Started
- 19 Jun 2024
- Expected to end
- 1 Jul 2031
- Type of study
- Interventional
- Record updated
- 13 March 2025
Who can take part
- Age
- Up to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
- 18 years or older
- Proven first trimester primary CMV infection
Who cannot take part
- Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
- Participant has a history of kidney function problems, liver function problems, immunocomprimised
- Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
- Participation in an interventional Trial with an investigational medicinal product (IMP) or device
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to investigate the effectivity of valaciclovir to prevent vertical CMV transmission during pregnancy in first trimester primary maternal CMV infections.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Congenital CMV treated with valaciclovir during pregnancy: a prospective cohort study
- Record updated
- 13 March 2025